Overview

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborators:
Epidermolysis Bullosa Research Partnership
Menlo Therapeutics
Treatments:
Neurokinin A
Neurokinin-1 Receptor Antagonists
Serlopitant
Substance P